SAN DIEGO, June 25 (Reuters) - A new type of diabetes pill being developed by Bristol-Myers Squibb (BMY.N) and AstraZeneca (AZN.L) was effective in a two-year study, but the companies said more bladder and breast cancers have been seen in patients treated with the drug.
In an update on the incidence of malignancies in all studies so far completed, 1.4 percent of patients treated with dapagliflozin developed some type of cancer, compared with 1.3 percent of control group patients, said Elisabeth Bjork, vice president of development for dapagliflozin at AstraZeneca.
It is potentially the first in a new class of diabetes drugs designed to block glucose from being absorbed into the bloodstream though the kidneys -- allowing more sugar to be excreted with urine.
Analysts have forecast Bristol-Myers’ annual dapagliflozin sales at $631 million by 2015, according to Thomson Pharma.
Editing by Sandra Maler